Literature DB >> 19610049

Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma.

Jordi Rimola1, Alejandro Forner, Maria Reig, Ramon Vilana, Carlos Rodríguez de Lope, Carmen Ayuso, Jordi Bruix.   

Abstract

This study assesses the magnetic resonance (MR) features of intrahepatic cholangiocarcinoma (ICC) in patients with cirrhosis with specific analysis of the contrast enhancement pattern. Cholangiocarcinoma may show increased contrast uptake in the arterial phase, and, if washout in the delayed venous phase were to be detected, the noninvasive diagnostic criteria proposed in the American Association for the Study of Liver Diseases guidelines would be refuted. We reviewed the MR findings of 25 patients with cirrhosis with 31 histologically confirmed ICC nodules. Signal intensity on basal T1-weighted and T2-weighted images and characteristics of enhancement after contrast administration on arterial, portal, and delayed phase were registered. Enhancement pattern was defined according to the behavior of the lesions in each phase, and dynamic pattern was described according to the progression of enhancement throughout the different phases. The most frequent pattern displayed by ICC was a progressive contrast uptake (80.6%). Stable contrast enhancement was registered in 19.4%. None of the ICCs showed a washout pattern, a profile that is specific for hepatocellular carcinoma (HCC). The ICC dynamic behavior differed significantly according to tumor size: progressive enhancement pattern was the most frequent (20 of 25 cases) in lesions larger than 20 mm, whereas the stable pattern was mainly identified in nodules smaller than 20 mm. The most characteristic MR contrast pattern in ICC in cirrhosis is a progressive contrast uptake throughout the different phases, whereas contrast washout at delayed phases is not observed. Because stable enhancement pattern without washout also can be registered in small HCC nodules, the evaluation of delayed phase is mandatory for a proper nodule characterization. If washout is not registered, a biopsy should be mandatory for diagnosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19610049     DOI: 10.1002/hep.23071

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  76 in total

Review 1.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-09       Impact factor: 11.105

2.  Cholangiocarcinoma: another masquerader in the making?

Authors:  Karthik Gnanapandithan; Satya Allaparthi; Thomas Ukena; Curuchi Anand
Journal:  J Gastrointest Cancer       Date:  2014-12

Review 3.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

4.  Different MR features for differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma according to tumor size.

Authors:  Ting Ni; Xiao-Sha Shang; Wen-Tao Wang; Xin-Xing Hu; Meng-Su Zeng; Sheng-Xiang Rao
Journal:  Br J Radiol       Date:  2018-06-05       Impact factor: 3.039

5.  Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis.

Authors:  Julius Chapiro; Laura D Wood; MingDe Lin; Rafael Duran; Toby Cornish; David Lesage; Vivek Charu; Rüdiger Schernthaner; Zhijun Wang; Vania Tacher; Lynn Jeanette Savic; Ihab R Kamel; Jean-François Geschwind
Journal:  Radiology       Date:  2014-07-15       Impact factor: 11.105

6.  The challenges of novel contrast agents for the imaging diagnosis of hepatocellular carcinoma.

Authors:  Carmen Ayuso; Jordi Bruix
Journal:  Hepatol Int       Date:  2013-12-28       Impact factor: 6.047

Review 7.  Nodule in Liver: Investigations, Differential Diagnosis and Follow-up.

Authors:  Padaki N Rao
Journal:  J Clin Exp Hepatol       Date:  2014-07-23

Review 8.  Radiological diagnosis of hepatocellular carcinoma.

Authors:  Mark W Russo; Christoph Wald
Journal:  Clin Liver Dis (Hoboken)       Date:  2013-01-23

Review 9.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

Review 10.  Magnetic resonance evaluations of biliary malignancy and condition at high-risk for biliary malignancy: Current status.

Authors:  Reiji Sugita
Journal:  World J Hepatol       Date:  2013-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.